Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The aim of this study was to understand the epidemiology, disease severity, and microbiology of bronchiolitis in Italy during the 2021-2022 cold season, outside of lockdowns. Before COVID-19, the usual bronchiolitis season in Italy would begin in November and end in April, peaking in February. We performed a prospective observational study in four referral pediatric centers located in different geographical areas in Italy (two in the north, one in the center and one in the south). From 1 July 2021 to 31 January 2022, we collected all new clinical diagnoses of bronchiolitis in children younger than two years of age recording demographic, clinical and microbiological data. A total of 657 children with a clinical diagnosis of bronchiolitis were enrolled; 56% children were admitted and 5.9% required PICU admission. The first cases were detected during the summer, peaking in November 2021 and declining into December 2021 with only a few cases detected in January 2022. RSV was the commonest etiological agent, while SARS-CoV-2 was rarely detected and only since the end of December 2021. Disease severity was similar in children with RSV vs. non-RSV bronchiolitis, and in those with a single infectious agent detected compared with children with co-infections. The 2021-2022 bronchiolitis season in Italy started and peaked earlier than the usual pre-pandemic seasons, but had a shorter duration. Importantly, the current bronchiolitis season was not more severe when data were compared with Italian published data, and SARS-CoV-2 was rarely a cause of bronchiolitis in children younger than 24 months of age.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024462PMC
http://dx.doi.org/10.3390/children9040491DOI Listing

Publication Analysis

Top Keywords

bronchiolitis season
12
bronchiolitis
9
cold season
8
geographical areas
8
areas italy
8
prospective observational
8
observational study
8
disease severity
8
season italy
8
january 2022
8

Similar Publications

BACKGROUNDThe COVID-19 pandemic underscored the need and value of a standardised and timely surveillance system for severe acute respiratory infections (SARI) to inform epidemic preparedness and response.AIMWe aimed to develop an automated SARI surveillance system using electronic health records retrieved from pre-existing national health registers in Denmark.METHODSWe used the Danish Civil Register, the Danish National Patient Register and the Danish Microbiology Database to set up the system.

View Article and Find Full Text PDF

Effectiveness of a targeted infant RSV immunization strategy (2024-2025): A multicenter matched case-control study in a high-surveillance setting.

J Infect

August 2025

Meyer Children's Hospital, IRCCS, Pediatric Unit, Florence, Italy; Department of Neurosciences, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.

Background: Nirsevimab, a long-acting monoclonal antibody against respiratory syncytial virus (RSV), was recently introduced to prevent infant RSV-related hospitalizations. Although efficacy has been demonstrated in clinical trials, real-world data on targeted immunization strategies remain limited. We aimed to evaluate the effectiveness of nirsevimab in preventing RSV-associated hospitalizations in infants under 12 months, within a seasonal program prioritizing infants born from April onwards.

View Article and Find Full Text PDF

Background And Objectives: Spain was among the first countries to implement universal prophylaxis for respiratory syncytial virus (RSV) using nirsevimab, leading to a 60%-80% reduction in bronchiolitis hospital admissions. The main objective of this study was to describe the characteristics of infants admitted with bronchiolitis after RSV prophylaxis had been established.

Methods: A retrospective study was conducted in 15 Spanish pediatric emergency departments during the 2023-2024 RSV season.

View Article and Find Full Text PDF

Bronchiolitis is the leading cause of hospitalization in infants under 12 months. While often self-limiting, a subset of cases evolves into severe disease requiring intensive care. This study aimed to identify risk factors for severe bronchiolitis in two consecutive respiratory syncytial virus (RSV) seasons (before and after the introduction of nirsevimab) in Southern Italy.

View Article and Find Full Text PDF

This study assessed the direct costs of using Palivizumab for RSV prevention in the Foggia District, Italy, during the 2023/2024 season, and explored the cost savings coming from reallocating resources to Nirsevimab in a universal RSV program. Switching from Palivizumab to Nirsevimab could protect 57.85 % of newborns per season.

View Article and Find Full Text PDF